Aeglea Biotherapeutics Raises $44M

Austin-based Aeglea Biotherapeutics, a biopharmaceuticals developer aiming at helping treat metabolism-based disease, has raised $44M in a Series B funding round. The funding was led by Illy Ventures and Novartis Venture Fund, and also included UT Horizon Fund, OrbiMed, Jennison Associates, Venrock, RA Capital Management, Rock Springs Capital, Ally Bridge Group, and Cowen Investments. Aeglea is working on engineered enzymes to degrade excessive amino acids, the cause of many metabolism diseases and tumors. Aeglea is led by David G. Lowe. More information »